Compare CVS Health Corp (CVS) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Ralph Lauren Corp — how do they compare? CVS Health Corp trades at $106.54 (market cap $135.48B), while Ralph Lauren Corp trades at $375.5 (market cap $21.96B). The key difference: CVS Health Corp is far larger — about 6.2× Ralph Lauren Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | RL | |
|---|---|---|
Market Cap | $135.48B | $21.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $106.18 | $414.25 |
52-Week Low | $58.75 | $283.34 |
Enterprise Value | $202.02B | $22.90B |
Dividend Yield | 2.51% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Ralph Lauren (RL) trades at $374.49, down 5.17% on the day, showing bearish technical momentum despite strong fundamentals. The company demonstrates robust financial performance with consistent earnings beats, including Q1 2026 EPS of $2.80 beating expectations of $2.55. Revenue growth accelerated to $7.08 billion in 2025 with net income margin expanding to 10.49%. Analyst consensus remains strongly bullish with 66% buy ratings and a $446.25 price target representing 19% upside potential.
The stock presents a compelling growth opportunity with strong brand momentum and digital expansion driving performance, though premium valuation metrics and technical bearish signals warrant caution. Key risks include macroeconomic sensitivity and competitive pressures in the apparel sector, while institutional sentiment remains positive given the company's execution on its Next Great Chapter strategy and Asia growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
